Schizophrenia
Conditions
Brief summary
This study will assess transcranial magnetic stimulation (TMS) as a biomarker and characterize TMS readouts of the activity of MK2637 and dextromethorphan. Resting quantitative electroencephalography(qEEG) readouts are also characterized with MK2637 and dextromethorphan.
Interventions
DRUGMK2637
Single dose of 120 mg MK2637 capsules in one of five treatment periods.
DRUGComparator: MK2637
Single dose of 50 mg MK2637 capsules in one of five treatment periods.
DRUGComparator: Placebo
Single dose of placebo only in one of five treatment periods.
DRUGComparator: Dextromethorphan
Single dose of 220 mg dextromethorphan capsules in one of five treatment periods.
Sponsors
Merck Sharp & Dohme LLC
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
MALE
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Subject is right-handed * Subject is in good health * Subject is a nonsmoker
Exclusion criteria
* Subject works a night shift * Subject has a history of any illness that might make participation in the study unsafe or confound the study results * Subject has a history of head injury
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Increase in Motor Evoked Potential (MEP) after dosing with dextromethorphan compared to placebo | 5 Hours after initial dosing |
| Increase in amplitude in the gamma frequency band (24-60 Hz) of resting qEEG after dosing with dextromethorphan compared to placebo | 4 Hours after initial dosing |
Secondary
| Measure | Time frame |
|---|---|
| Increase in amplitude in the theta frequency band (4-8 Hz) of resting qEEG after dosing with MK2637 compared to placebo | 6.5 hours after initial dosing |
| Change in Motor Evoked Potential (MEP) after dosing with MK2637 as compared to placebo | 5 hours after initial dosing |
Outcome results
None listed